Log in | Register

Fluid type and the use of renal replacement therapy in sepsis: a systematic review and network meta-analysis

B. Rochwerg| W. Alhazzani| A Gibson| C. M. Ribic| A. Sindi| D. Heels-Ansdell| L. Thabane| A. Fox-Robichaud| L. Mbuagbaw| W. Szczeklik| F. Alshamsi| S. Altayyar| W. Ip| G. Li| M. Wang| A. Włudarczyk| Q. Zhou| D. Annane| D. J. Cook| R. Jaeschke| G. H. Guyatt
Systematic Review
Volume 41, Issue 9 / September , 2015

Pages 1561 - 1571

Abstract

Fluid resuscitation, along with the early administration of antibiotics, is the cornerstone of treatment for patients with sepsis. However, whether differences in resuscitation fluids impact on the requirements for renal replacement therapy (RRT) remains unclear. To examine this issue, we performed a network meta-analysis (NMA), including direct and indirect comparisons, that addressed the effect of different resuscitation fluids on the use of RRT in patients with sepsis. The data sources MEDLINE, EMBASE, ACPJC, CINAHL and Cochrane Central Register were searched up to March 2014. Eligible studies included randomized trials reported in any language that enrolled adult patients with sepsis or septic shock and addressed the use of RRT associated with alternative resuscitation fluids. The risk of bias for individual studies and the overall certainty of the evidence were assessed. Ten studies (6664 patients) that included a total of nine direct comparisons were assessed. NMA at the four-node level showed that an increased risk of receiving RRT was associated with fluid resuscitation with starch versus crystalloid [odds ratio (OR) 1.39, 95 % credibility interval (CrI) 1.17–1.66, high certainty]. The data suggested no difference between fluid resuscitation with albumin and crystalloid (OR 1.04, 95 % CrI 0.78–1.38, moderate certainty) or starch (OR 0.74, 95 % CrI 0.53–1.04, low certainty). NMA at the six-node level showed a decreased risk of receiving RRT with balanced crystalloid compared to heavy starch (OR 0.50, 95 % CrI 0.34–0.74, moderate certainty) or light starch (OR 0.70, 95 % CrI 0.49–0.99, high certainty). There was no significant difference between balanced crystalloid and saline (OR 0.85, 95 % CrI 0.56–1.30, low certainty) or albumin (OR 0.82, 95 % CrI 0.49–1.37, low certainty). Of note, these trials vary in terms of case mix, fluids evaluated, duration of fluid exposure and risk of bias. Imprecise estimates contributed to low confidence in most estimates of effect. Among the patients with sepsis, fluid resuscitation with crystalloids compared to starch resulted in reduced use of RRT; the same may be true for albumin versus starch.

Keywords

References

  1. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C (2005) Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813–818
    • View reference on publisher's website
    • View reference on PubMed
  2. Bagshaw SM, Laupland KB, Doig CJ, Mortis G, Fick GH, Mucenski M, Godinez-Luna T, Svenson LW, Rosenal T (2005) Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit care (London) 9:R700–R709
    • View reference on publisher's website
  3. Neveu H, Kleinknecht D, Brivet F, Loirat P, Landais P (1996) Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French study group on acute renal failure. Nephrol Dial Transpl 11:293–299
    • View reference on publisher's website
  4. Wald R, Quinn RR, Adhikari NK, Burns KE, Friedrich JO, Garg AX, Harel Z, Hladunewich MA, Luo J, Mamdani M, Perl J, Ray JG (2012) Risk of chronic dialysis and death following acute kidney injury. Am J Med 125:585–593
    • View reference on publisher's website
    • View reference on PubMed
  5. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377
    • View reference on publisher's website
    • View reference on PubMed
  6. Prowle JR, Echeverri JE, Ligabo EV, Ronco C, Bellomo R (2010) Fluid balance and acute kidney injury. Nat Rev Nephrol 6:107–115
    • View reference on publisher's website
    • View reference on PubMed
  7. Antonelli M, Azoulay E, Bonten M, Chastre J, Citerio G, Conti G, De Backer D, Gerlach H, Hedenstierna G, Joannidis M, Macrae D, Mancebo J, Maggiore SM, Mebazaa A, Preiser JC, Pugin J, Wernerman J, Zhang H (2011) Year in review in intensive care medicine 2010: I. Acute renal failure, outcome, risk assessment and ICU performance, sepsis, neuro intensive care and experimentals. Intensive Care Med 37:19–34
  8. Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declere AD, Preiser JC, Outin H, Troche G, Charpentier C, Trouillet JL, Kimmoun A, Forceville X, Darmon M, Lesur O, Regnier J, Abroug F, Berger P, Clech C, Cousson J, Thibault L, Chevret S (2013) Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 310:1809–1817
    • View reference on publisher's website
    • View reference on PubMed
  9. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H (2012) Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Critical Care 16:R94
    • View reference on publisher's website
    • View reference on PubMed
  10. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA, for the CHEST Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901–1911
    • View reference on publisher's website
    • View reference on PubMed
  11. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP, Winkel P, Wetterslev J, Group ST, Scandinavian Critical Care Trials Group (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134
    • View reference on publisher's website
    • View reference on PubMed
  12. U.S. Food and Drug Administration (2013) FDA Safety Communication: boxed warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. Available at: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm358271.htm
  13. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247–2256
    • View reference on publisher's website
    • View reference on PubMed
  14. Rochwerg B, Wludarczyk A, Szczeklik W, Alhazzani W, Sindi A, Alshamsi F, Ip WC, Wang M, Altayyar S, Li G, Fox-Robichaud A, Guyatt G, group F (2013) Fluid resuscitation in severe sepsis and septic shock: systematic description of fluids used in randomized trials. Pol Arch Med Wewn 123:603–608
    • View reference on PubMed
  15. Morgan TJ (2013) The ideal crystalloid—what is balanced? Curr Opin Crit Care 19:299–307
    • View reference on publisher's website
    • View reference on PubMed
  16. Lobo DN (2012) Intravenous 0.9% saline and general surgical patients: a problem, not a solution. Ann Surg 255:830–832
    • View reference on publisher's website
    • View reference on PubMed
  17. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M (2012) Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308:1566–1572
    • View reference on publisher's website
    • View reference on PubMed
  18. Jiwaji Z, Brady S, McIntyre LA, Gray A, Walsh TS (2013) Emergency department management of early sepsis: a national survey of emergency medicine and intensive care consultants. Emerg Med J 31:1000–1005
    • View reference on publisher's website
    • View reference on PubMed
  19. Jones D, McEvoy S, Merz TM, Higgins A, Bellomo R, Cooper JD, Hollis S, McArthur C, Myburgh JA, Taylor C, Liu B, Norton R, Finfer S (2010) International albumin use: 1995 to 2006. Anaesth Intensive Care 38:266–273
    • View reference on PubMed
  20. Siegemund M (2011) BaSES Trial: Basel Starch Evaluation in Sepsis. ClinicalTrials.gov Identifier: NCT00273728. Available at: https://clinicaltrials.gov/ct2/show/study/NCT00273728
  21. Rochwerg B, Alhazzani W, Sindi A, Heels-Ansdell D, Thabane L, Fox-Robichaud A, Mbuagbaw L, Szczeklik W, Alshamsi F, Altayyar S, Ip WC, Li G, Wang M, Wludarczyk A, Zhou Q, Guyatt GH, Cook DJ, Jaeschke R, Annane D (2014) Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med 161:347–355
    • View reference on publisher's website
    • View reference on PubMed
  22. Miller DR (2011) Update to readers and authors on ethical and scientific misconduct: retraction of the Boldt articles. Can J Anaesth 58(777–779):779–781
  23. Guyatt GH, Busse J (2011) Methods commentary: risk of bias in randomized trials 1. Evidence Partners. http://distillercer.com/resources/methodological-resources/risk-of-bias-commentary/. Accessed 13 Sept 2013
  24. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
    • View reference on publisher's website
    • View reference on PubMed
  25. Jansen JP, Cope S (2012) Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Method 12:152
    • View reference on publisher's website
  26. Jansen JP, Naci H (2013) Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med Res Method 11:159
    • View reference on publisher's website
  27. Mills EJ, Ioannidis JP, Thorlund K, Schunemann HJ, Puhan MA, Guyatt GH (2012) How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 308:1246–1253
    • View reference on publisher's website
    • View reference on PubMed
  28. Gelman ARD (1992) Inferences from iterative simulation using multiple sequences. Stat Sci 7:457–472
    • View reference on publisher's website
  29. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH (2011) GRADE guidelines: 3 rating the quality of evidence. J Clin Epidemiol 64:401–406
    • View reference on publisher's website
    • View reference on PubMed
  30. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926
    • View reference on publisher's website
    • View reference on PubMed
  31. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, Kessels AG, Guyatt GH (2014) A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349:g5630
    • View reference on publisher's website
    • View reference on PubMed
  32. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139
    • View reference on publisher's website
    • View reference on PubMed
  33. McIntyre LA, Fergusson D, Cook DJ, Rankin N, Dhingra V, Granton J, Magder S, Stiell I, Taljaard M, Hebert PC (2008) Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trial. Can J Anaesth 55:819–826
    • View reference on publisher's website
    • View reference on PubMed
  34. Schortgen F, Lacherade J-C, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L (2001) Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357:911–916
    • View reference on publisher's website
    • View reference on PubMed
  35. Dubin A, Pozo MO, Casabella CA, Murias G, Palizas F Jr, Moseinco MC, Kanoore Edul VS, Palizas F, Estenssoro E, Ince C (2010) Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients. J Crit Care 25: 659 e651–658
  36. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250–1256
    • View reference on publisher's website
    • View reference on PubMed
  37. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S, Committee CM (2012) Fluid resuscitation with 6% hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. Anesth Analg 114:159–169
    • View reference on publisher's website
    • View reference on PubMed
  38. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J (2013) Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 346:f839
    • View reference on publisher's website
    • View reference on PubMed
  39. Patel A, Waheed U, Brett SJ (2013) Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med 39:811–822
  40. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678–688
    • View reference on publisher's website
    • View reference on PubMed
  41. Zarychanski R, Turgeon AF, Fergusson DA, Cook DJ, Hebert P, Bagshaw SM, Monsour D, McIntyre L (2009) Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 3(4):e196–e209 [ATTENTION: The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia’s retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia’s press release]
  42. Yunos NM, Kim IB, Bellomo R, Bailey M, Ho L, Story D, Gutteridge GA, Hart GK (2011) The biochemical effects of restricting chloride-rich fluids in intensive care. Crit Care Med 39:2419–2424
    • View reference on publisher's website
    • View reference on PubMed
  43. Dai ZL, Wu J, Meng C, Zeng F, Yang Y, Yao SL (2012) Ringer’s malate solution protects against the multiple organ injury and dysfunction caused by hemorrhagic shock in rats. Shock 38:268–274
    • View reference on publisher's website
    • View reference on PubMed
  44. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L (2014) Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 370:1412–1421
    • View reference on publisher's website
    • View reference on PubMed
  45. Charpentier J, Mira JP, EARSS Study Group (2011) Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: the EARSS study [abstract]. Intensive Care Med; 37(Suppl 2):S115–S438
  46. Raghunathan K, Murray PT, Beattie WS, Lobo DN, Myburgh J, Sladen R, Kellum JA, Mythen MG, Shaw AD (2014) Choice of fluid in acute illness: what should be given? An international consensus. Br J Anaesth 113:772–783
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement